uniQure N.V. Products & Brands - Key Offerings and Insights

Products

Category

Product

Brand

Description

Global Market for Cell and Gene Therapy (BIO225B)

Hemgenix (etranacogene dezaparvovec)

The FDA approved Hemgenix (etranacogene dezaparvovec) as the first gene therapy for hemophilia B and UniQure's second internally developed gene therapy to receive approval. In February 2023, Hemgenix received conditional marketing authorization (CMA) from the EC, making it the first one-time gene therapy for hemophilia in the EU.

This information is available for BCC Research members only.

Already a Member? Sign In Become a Member

Stay Informed

Join our mailing list for the latest report releases and upcoming event notifications.

Headquartered in Boston, Mass., for over 50 years, BCC Research takes pride in being your trusted custom research and data analysts. Our mission is to provide businesses with reputable data and market research reports, so that they gain new perspectives into their field and better understand their target audience. We enable companies to access reliable information, accurate forecasts, and actionable insights, so that they may become leaders in their industry.